Literature DB >> 11870168

Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

Lauren Scheuer1, Noah Kauff, Mark Robson, Bridget Kelly, Richard Barakat, Jaya Satagopan, Nathan Ellis, Martee Hensley, Jeff Boyd, Patrick Borgen, Larry Norton, Kenneth Offit.   

Abstract

PURPOSE: To prospectively determine the impact of genetic counseling and testing on risk-reduction strategies and cancer incidence in a cohort of individuals at hereditary risk for breast and ovarian cancer. PATIENTS AND METHODS: Two hundred fifty-one individuals with BRCA mutations were identified at a single comprehensive cancer center from May 1, 1995, through October 31, 2000. Uniform recommendations regarding screening and preventive surgery were provided in the context of genetic counseling. Patients were followed for a mean of 24.8 months (range, 1.6 to 66.0 months) using standardized questionnaires, chart reviews, and contact with primary physicians.
RESULTS: Frequency of cancer surveillance by physical examinations and imaging studies increased after genetic counseling and testing. Twenty-one breast, ovarian, primary peritoneal, or fallopian tube cancers were detected after receipt of genetic test results. Among 29 individuals choosing risk-reducing mastectomy after testing, two were found to have occult intraductal breast cancers. Among 90 individuals who underwent risk-reducing salpingo-oophorectomy, one early-stage ovarian neoplasm and one early-stage fallopian tube neoplasm were found. Radiographic or tumor marker-based screening detected six breast cancers, five of which were stage 0/I, one early-stage primary peritoneal cancer, and three stage I or II ovarian cancers. Six additional breast cancers were detected by physical examination between radiographic screening intervals; four of these six tumors were stage I. No stage III or stage IV malignancies were detected after genetic testing.
CONCLUSION: This study provides prospective evidence that genetic counseling and testing increased surveillance and led to risk-reducing operations, which resulted in diagnosis of early-stage tumors in patients with BRCA1 and BRCA2 mutations.

Entities:  

Mesh:

Year:  2002        PMID: 11870168     DOI: 10.1200/JCO.2002.20.5.1260

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  97 in total

1.  Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.

Authors:  Janie M Lee; Pamela M McMahon; Chung Y Kong; Daniel B Kopans; Paula D Ryan; Elissa M Ozanne; Elkan F Halpern; G Scott Gazelle
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

2.  Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.

Authors:  Soley Bayraktar; Nisreen Elsayegh; Angelica M Gutierrez Barrera; Heather Lin; Henry Kuerer; Tunc Tasbas; Kimberly I Muse; Kaylene Ready; Jennifer Litton; Funda Meric-Bernstam; Gabriel N Hortobagyi; Constance T Albarracin; Banu Arun
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

3.  Screening behavior in women at increased familial risk for breast cancer.

Authors:  Yoland C Antill; John Reynolds; Mary Anne Young; Judy A Kirk; Katherine M Tucker; Tarli L Bogtstra; Shirley S Wong; Tracy E Dudding; Juliana L Di Iulio; Kelly-Anne Phillips
Journal:  Fam Cancer       Date:  2006-07-07       Impact factor: 2.375

4.  Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing.

Authors:  Vardit Kram; Tamar Peretz; Michal Sagi
Journal:  Fam Cancer       Date:  2006-05-25       Impact factor: 2.375

Review 5.  Predictors of choosing life-long screening or prophylactic surgery in women at high and moderate risk for breast and ovarian cancer.

Authors:  J R J De Leeuw; M J van Vliet; M G E M Ausems
Journal:  Fam Cancer       Date:  2008-03-14       Impact factor: 2.375

Review 6.  Patient responses to genetic information: studies of patients with hereditary cancer syndromes identify issues for use of genetic testing in nephrology practice.

Authors:  Kimberly A Kaphingst; Colleen M McBride
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

7.  High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.

Authors:  Banu Arun; Kristen J Vogel; Adriana Lopez; Mike Hernandez; Deann Atchley; Kristine R Broglio; Christopher I Amos; Funda Meric-Bernstam; Henry Kuerer; Gabriel N Hortobagyi; Constance T Albarracin
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-27

8.  Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years.

Authors:  Karin M Landsbergen; Judith B Prins; Yvonne J L Kamm; Han G Brunner; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

9.  Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation.

Authors:  Jennifer K Litton; Shannon N Westin; Kaylene Ready; Charlotte C Sun; Susan K Peterson; Funda Meric-Bernstam; Ana M Gonzalez-Angulo; Diane C Bodurka; Karen H Lu; Gabriel N Hortobagyi; Banu K Arun
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

10.  Colorectal cancer risk perception on the basis of genetic test results in individuals at risk for Lynch syndrome.

Authors:  Shilpa Grover; Elena M Stoffel; Rowena C Mercado; Beth M Ford; Wendy K Kohlman; Kristen M Shannon; Peggy G Conrad; Amie M Blanco; Jonathan P Terdiman; Stephen B Gruber; Daniel C Chung; Sapna Syngal
Journal:  J Clin Oncol       Date:  2009-07-20       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.